- Reichenstein, Irit;
- Eitan, Chen;
- Diaz-Garcia, Sandra;
- Haim, Guy;
- Magen, Iddo;
- Siany, Aviad;
- Hoye, Mariah;
- Rivkin, Natali;
- Olender, Tsviya;
- Toth, Beata;
- Ravid, Revital;
- Mandelbaum, Amitai;
- Yanowski, Eran;
- Liang, Jing;
- Rymer, Jeffrey;
- Levy, Rivka;
- Beck, Gilad;
- Ainbinder, Elena;
- Farhan, Sali;
- Lennox, Kimberly;
- Bode, Nicole;
- Behlke, Mark;
- Möller, Thomas;
- Saxena, Smita;
- Moreno, Cristiane;
- Costaguta, Giancarlo;
- van Eijk, Kristel;
- Phatnani, Hemali;
- Al-Chalabi, Ammar;
- Başak, A;
- van den Berg, Leonard;
- Hardiman, Orla;
- Landers, John;
- Mora, Jesus;
- Morrison, Karen;
- Shaw, Pamela;
- Veldink, Jan;
- Pfaff, Samuel;
- Yizhar, Ofer;
- Gross, Christina;
- Brown, Robert;
- Ravits, John;
- Harms, Matthew;
- Miller, Timothy;
- Hornstein, Eran
Motor neuron-specific microRNA-218 (miR-218) has recently received attention because of its roles in mouse development. However, miR-218 relevance to human motor neuron disease was not yet explored. Here, we demonstrate by neuropathology that miR-218 is abundant in healthy human motor neurons. However, in amyotrophic lateral sclerosis (ALS) motor neurons, miR-218 is down-regulated and its mRNA targets are reciprocally up-regulated (derepressed). We further identify the potassium channel Kv10.1 as a new miR-218 direct target that controls neuronal activity. In addition, we screened thousands of ALS genomes and identified six rare variants in the human miR-218-2 sequence. miR-218 gene variants fail to regulate neuron activity, suggesting the importance of this small endogenous RNA for neuronal robustness. The underlying mechanisms involve inhibition of miR-218 biogenesis and reduced processing by DICER. Therefore, miR-218 activity in motor neurons may be susceptible to failure in human ALS, suggesting that miR-218 may be a potential therapeutic target in motor neuron disease.